Kevin Stein, MD
Dermatology · Winston Salem, NCNPI 1730221037
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 57.3% of the total. Reporting peaked in 2019 at $3,871 and has fallen 77.3% since, to $879 in 2025.
Across 314 payments — averaging $32.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Sun Pharmaceutical Industries Inc.$698
- Novartis$481
- E.r. Squibb & Sons, L.L.C.$434
- Lilly USA, LLC$386
- Johnson & Johnson$322
- plus $2K from 18 others
Across 37 payments — averaging $30,898 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$851K
- Takeda Pharmaceuticals U.S.A., Inc.$262K
- UCB SA$30K
What the payments were for
- Consulting fees$3,80038%
- Travel & lodging$6757%
- Food & beverage$5,26152%
- Education$3914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $5,802 |
| Sun Pharmaceutical Industries Inc. | 34 | $698 |
| Novartis | 29 | $481 |
| E.r. Squibb & Sons, L.L.C. | 42 | $434 |
| Lilly USA, LLC | 19 | $386 |
| Johnson & Johnson | 20 | $322 |
| Regeneron Healthcare Solutions, Inc. | 14 | $272 |
| Pfizer | 15 | $267 |
| Amgen | 12 | $246 |
| Sanofi | 10 | $210 |
| Arcutis Biotherapeutics, Inc. | 7 | $135 |
| Abbott | 1 | $118 |
| Almirall LLC | 3 | $114 |
| UCB, Inc. | 5 | $100 |
| Incyte Corporation | 5 | $94 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $85 |
| Dermavant Sciences, Inc. | 4 | $82 |
| LEO Pharma Inc. | 4 | $70 |
| Biofrontera Inc. | 3 | $47 |
| Galderma Laboratories, L.p. | 2 | $42 |
| Bristol Myers Squibb | 3 | $37 |
| DUSA Pharmaceuticals, Inc. | 2 | $33 |
| Dermira, Inc. | 2 | $31 |
| Boehringer Ingelheim | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,127 in reported general payments places this provider in the 80th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 40 | $467,371 |
| Dupixent PenDupilumab | 36 | $134,065 |
| OtezlaApremilast | 18 | $87,290 |
| Dupixent SyringeDupilumab | 14 | $51,749 |
| Fluorouracil | 100 | $7,744 |
| Clobetasol Propionate | 102 | $3,158 |
| Triamcinolone Acetonide | 256 | $2,041 |
| Metronidazole | 34 | $1,767 |
| Ketoconazole | 78 | $1,727 |
| Fluocinonide | 38 | $1,548 |
| Clindamycin Phosphate | 34 | $1,163 |
| Doxycycline Hyclate | 50 | $1,118 |
| Betamethasone Dipropionate | 29 | $1,033 |
| Mometasone Furoate | 45 | $1,009 |
| Betamethasone Valerate | 26 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $246 | $87,29018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 475 dermatology providers in North Carolina.
Other dermatology in Winston Salem
- Steven FeldmanWinston Salem$3.4M
- Amy McMichaelWinston Salem$309K
- Joseph JorizzoWinston Salem$20K
- David SpencerWinston Salem$14K
- Nicole SeminaraHuntersville$1.4M
- Andrew LeeElkin$702K
- Christopher SayedChapel Hill$690K
- William HooverConcord$594K
- Patrick McElgunnCharlotte$565K
- George MagelHickory$554K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.